News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

ALL CONTRIBUTIONS

Week In Review: BioKangtai Acquires China Rights To AstraZeneca's COVID-19 Vaccine
BioKangtai, a Guangdong vaccine company, in-licensed rights to develop, manufacture, and market AstraZeneca's COVID-19 vaccine in China. Biogen announced a $2 billion deal to partner Denali Therapeutics' potential Parkinson's Disease therapy.
Read
Week In Review: Shanghai Hansoh Enters $68 Million Deal For Leukemia Candidate
Shanghai Hansoh Pharma obtained Greater China rights to a BCR-ABL inhibitor discovered by Terns Pharma of California. Hansoh will make an upfront payment, plus milestones of up to $68 million. It will also pay royalties on sales.
Read
Week In Review: BeiGene Signs $540 Million Deal For China Rights To Three HBV Candidates
Beijing's BeiGene in-licensed Greater China rights to three inhibitors for chronic hepatitis B virus from Assembly Bio in a $540 million agreement. BeiGene, which will make a $40 million upfront payment, is responsible for $500 million in milestones.
Read
Week In Review: China Life Science Announces $5 Billion In Deals, A Weekly Record
BeiGene, a Beijing oncology drug biopharma, announced a $2.1 billion private placement that will bring its cash holdings to almost $5.5 billion The company is developing a portfolio of 25 candidates, with several of them in Phase III tests.
Read
Week In Review: Ocumension Climbs To $2.5 Billion Market Cap After $184 Million Hong Kong IPO
Ocumension, a Shanghai ophthalmic pharma, completed a $184 million Hong Kong IPO and climbed 152% in its first trading session, giving the company a valuation of about $2.5 billion. The company has raised $200 million in venture capital.
Read
Week In Review: China Life Science Announces Deals Worth $1.3 Billion
Boehringer Ingelheim launched its External Innovation Hub China in Shanghai to increase the company's China R&D partnerships.. The Hub has $508 million to spend on China clinical research, expansion of production sites and research partnerships.
Read

STOCKS I FOLLOW

AXN Aoxing Pharmaceutical Company, Inc.
CRPNF China Pioneer Pharma Holdings Ltd.
CYIG CHINA YCT INTL GROUP
HCM Hutchison Chi-Med
ICLR Icon PLC
MCRPF MICROPORT SCIENTIFIC
MDCO The Medicines Company
MR Mindray Medical International Limited
NBY NovaBay Pharmaceuticals, Inc.
SCLN SciClone Pharmaceuticals, Inc.
WX WuXi PharmaTech Inc.
Load More

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications